FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation

Biofarmaceutski sistem klasifikacije (BSK) kao osnova za selektivni pristup ispitivanju biološke raspoloživosti/biološke ekvivalentnosti (BA/BE) farmaceutskih preparata

Thumbnail
2006
735.pdf (273.6Kb)
Authors
Petronijević, Marija
Pokrajac, Milena
Miljković, Branislava
Vučićević, Katarina
Article (Published version)
Metadata
Show full item record
Abstract
One of fundamental investigations, that pharmaceutical industry is expected to conduct during development of pharmaceutical formulation in order to prove its efficiency and safety, is bioavailability (BA), or bioequivalence (BE) assessment. Traditional approach to this investigation entails strictly controlled, expensive and time consuming study in humans. The potential for considering drugs' in vivo behavior has been extended and new selective approach has been set by development of Biopharmaceutics Classification System (BCS) and evaluation of drug absorption according to solubility and permeability properties of the drug, as well as its dissolution from pharmaceutical preparation. Manufacturers are particularly interested in creating criteria based on BCS concept for granting waiver of BA/BE studies for Immediate Release Products (IRP), aiming for reduction of time and cost of drug development process. These criteria have been discussed at many experts' meetings lately, and regulato...ry agencies are expected in near future to consider proposals for changes in regulative requirements according to the results from practice. If some of them were accepted, BCS would become even more significant as a powerful tool in drug and pharmaceutical preparation development process.

U osnovi ispitivanja, koja proizvođač sprovodi tokom razvoja formulacije farmaceutskog preparata u cilju dokazivanja efikasnosti i bezbednosti, nalazi se ispitivanje biološke raspoloživosti (BR), odnosno relativne biološke raspoloživosti/biološke ekvivalentnosti (BE) preparata. Tradicionalni pristup ovom ispitivanju podrazumeva strogo kontrolisano, skupo i dugotrajno in vivo ispitivanje u ljudi. Razvojem biofarmaceutskog sistema klasifikacije (BSK) i procenom resorpcije lekovitih supstanci na osnovu njihove rastvorljivosti, permeabilnosti kroz membrane i brzine rastvaranja iz farmaceutskog preparata, proširene su mogućnosti za sagledavanje in vivo ponašanja lekova i postavljena osnova za savremeni, selektivni pristup ispitivanju BR/BE. Za proizvođače je od posebne važnosti upotreba BSK-a u postavljanju kriterijuma za oslobađanje konvencionalnih preparata od ispitivanja BR/BE (waiver of BA/BE studies), sa ciljem uštede vremena i novca u procesu razvoja leka. Ovi kriterijumi su poslednji...h godina predmet brojnih stručnih rasprava i u bliskoj budućnosti očekuje se da će regulatorne agencije razmotriti predloge za izmene u regulativi zasnovane na rezultatima iz prakse. Usvajanjem nekih od njih, BSK bi dobio još veći značaj kao moćno sredstvo u procesu razvoja lekovite supstance i farmaceutskih preparata.

Keywords:
Biopharmaceutics Classification System (BCS) / bioavailability (BA) / bioequivalence (BE) / biofarmaceutski sistem klasifikacije (BSK) / biološka raspoloživost (BK) / biološka ekvivalentnost (BE)
Source:
Arhiv za farmaciju, 2006, 56, 1, 1-15
Publisher:
  • Savez farmaceutskih udruženja Srbije, Beograd

ISSN: 0004-1963

[ Google Scholar ]
Handle
https://hdl.handle.net/21.15107/rcub_farfar_737
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/737
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/737
AB  - One of fundamental investigations, that pharmaceutical industry is expected to conduct during development of pharmaceutical formulation in order to prove its efficiency and safety, is bioavailability (BA), or bioequivalence (BE) assessment. Traditional approach to this investigation entails strictly controlled, expensive and time consuming study in humans. The potential for considering drugs' in vivo behavior has been extended and new selective approach has been set by development of Biopharmaceutics Classification System (BCS) and evaluation of drug absorption according to solubility and permeability properties of the drug, as well as its dissolution from pharmaceutical preparation. Manufacturers are particularly interested in creating criteria based on BCS concept for granting waiver of BA/BE studies for Immediate Release Products (IRP), aiming for reduction of time and cost of drug development process. These criteria have been discussed at many experts' meetings lately, and regulatory agencies are expected in near future to consider proposals for changes in regulative requirements according to the results from practice. If some of them were accepted, BCS would become even more significant as a powerful tool in drug and pharmaceutical preparation development process.
AB  - U osnovi ispitivanja, koja proizvođač sprovodi tokom razvoja formulacije farmaceutskog preparata u cilju dokazivanja efikasnosti i bezbednosti, nalazi se ispitivanje biološke raspoloživosti (BR), odnosno relativne biološke raspoloživosti/biološke ekvivalentnosti (BE) preparata. Tradicionalni pristup ovom ispitivanju podrazumeva strogo kontrolisano, skupo i dugotrajno in vivo ispitivanje u ljudi. Razvojem biofarmaceutskog sistema klasifikacije (BSK) i procenom resorpcije lekovitih supstanci na osnovu njihove rastvorljivosti, permeabilnosti kroz membrane i brzine rastvaranja iz farmaceutskog preparata, proširene su mogućnosti za sagledavanje in vivo ponašanja lekova i postavljena osnova za savremeni, selektivni pristup ispitivanju BR/BE. Za proizvođače je od posebne važnosti upotreba BSK-a u postavljanju kriterijuma za oslobađanje konvencionalnih preparata od ispitivanja BR/BE (waiver of BA/BE studies), sa ciljem uštede vremena i novca u procesu razvoja leka. Ovi kriterijumi su poslednjih godina predmet brojnih stručnih rasprava i u bliskoj budućnosti očekuje se da će regulatorne agencije razmotriti predloge za izmene u regulativi zasnovane na rezultatima iz prakse. Usvajanjem nekih od njih, BSK bi dobio još veći značaj kao moćno sredstvo u procesu razvoja lekovite supstance i farmaceutskih preparata.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation
T1  - Biofarmaceutski sistem klasifikacije (BSK) kao osnova za selektivni pristup ispitivanju biološke raspoloživosti/biološke ekvivalentnosti (BA/BE) farmaceutskih preparata
VL  - 56
IS  - 1
SP  - 1
EP  - 15
UR  - https://hdl.handle.net/21.15107/rcub_farfar_737
ER  - 
@article{
author = "Petronijević, Marija and Pokrajac, Milena and Miljković, Branislava and Vučićević, Katarina",
year = "2006",
abstract = "One of fundamental investigations, that pharmaceutical industry is expected to conduct during development of pharmaceutical formulation in order to prove its efficiency and safety, is bioavailability (BA), or bioequivalence (BE) assessment. Traditional approach to this investigation entails strictly controlled, expensive and time consuming study in humans. The potential for considering drugs' in vivo behavior has been extended and new selective approach has been set by development of Biopharmaceutics Classification System (BCS) and evaluation of drug absorption according to solubility and permeability properties of the drug, as well as its dissolution from pharmaceutical preparation. Manufacturers are particularly interested in creating criteria based on BCS concept for granting waiver of BA/BE studies for Immediate Release Products (IRP), aiming for reduction of time and cost of drug development process. These criteria have been discussed at many experts' meetings lately, and regulatory agencies are expected in near future to consider proposals for changes in regulative requirements according to the results from practice. If some of them were accepted, BCS would become even more significant as a powerful tool in drug and pharmaceutical preparation development process., U osnovi ispitivanja, koja proizvođač sprovodi tokom razvoja formulacije farmaceutskog preparata u cilju dokazivanja efikasnosti i bezbednosti, nalazi se ispitivanje biološke raspoloživosti (BR), odnosno relativne biološke raspoloživosti/biološke ekvivalentnosti (BE) preparata. Tradicionalni pristup ovom ispitivanju podrazumeva strogo kontrolisano, skupo i dugotrajno in vivo ispitivanje u ljudi. Razvojem biofarmaceutskog sistema klasifikacije (BSK) i procenom resorpcije lekovitih supstanci na osnovu njihove rastvorljivosti, permeabilnosti kroz membrane i brzine rastvaranja iz farmaceutskog preparata, proširene su mogućnosti za sagledavanje in vivo ponašanja lekova i postavljena osnova za savremeni, selektivni pristup ispitivanju BR/BE. Za proizvođače je od posebne važnosti upotreba BSK-a u postavljanju kriterijuma za oslobađanje konvencionalnih preparata od ispitivanja BR/BE (waiver of BA/BE studies), sa ciljem uštede vremena i novca u procesu razvoja leka. Ovi kriterijumi su poslednjih godina predmet brojnih stručnih rasprava i u bliskoj budućnosti očekuje se da će regulatorne agencije razmotriti predloge za izmene u regulativi zasnovane na rezultatima iz prakse. Usvajanjem nekih od njih, BSK bi dobio još veći značaj kao moćno sredstvo u procesu razvoja lekovite supstance i farmaceutskih preparata.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation, Biofarmaceutski sistem klasifikacije (BSK) kao osnova za selektivni pristup ispitivanju biološke raspoloživosti/biološke ekvivalentnosti (BA/BE) farmaceutskih preparata",
volume = "56",
number = "1",
pages = "1-15",
url = "https://hdl.handle.net/21.15107/rcub_farfar_737"
}
Petronijević, M., Pokrajac, M., Miljković, B.,& Vučićević, K.. (2006). Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 56(1), 1-15.
https://hdl.handle.net/21.15107/rcub_farfar_737
Petronijević M, Pokrajac M, Miljković B, Vučićević K. Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation. in Arhiv za farmaciju. 2006;56(1):1-15.
https://hdl.handle.net/21.15107/rcub_farfar_737 .
Petronijević, Marija, Pokrajac, Milena, Miljković, Branislava, Vučićević, Katarina, "Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation" in Arhiv za farmaciju, 56, no. 1 (2006):1-15,
https://hdl.handle.net/21.15107/rcub_farfar_737 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB